Department of Health and Human Services$1.1M obligationsEnds Dec 18, 2021
Federal contract award
75N92021F00003
HIGH THROUGHPUT GENOTYPING AND DNA SEQUENCING FOR STUDYING THE GENETIC CONTRIBUTIONS TO HUMAN HEALTH AND DISEASE: WHOLE EXOME SEQUENCING 90% AT 20X IN BLOOD/BUCCAL FOR NCI (DE VIVO)
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NHLBI |
| NAICS | 541712 |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | HHSN268201700006I |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $900.6K |
| Current contract value | $900.6K |
| Potential contract value / ceiling | $900.6K |
| Start date | Aug 4, 2021 |
| Current end date | Dec 31, 2025 |
| Potential end date | Dec 31, 2025 |
| Latest award activity | Jul 24, 2024 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 4 of 4 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 24, 2024 | P00003 | $0 | HIGH THROUGHPUT GENOTYPING AND DNA SEQUENCING FOR STUDYING THE GENETIC CONTRIBUTIONS TO HUMAN HEALTH AND DISEASE: WHOLE EXOME SEQUENCING 90% AT 20X IN BLOOD/BUCCAL FOR NCI (DE VIVO) |
| Dec 21, 2023 | P00002 | $0 | HIGH THROUGHPUT GENOTYPING AND DNA SEQUENCING FOR STUDYING THE GENETIC CONTRIBUTIONS TO HUMAN HEALTH AND DISEASE: WHOLE EXOME SEQUENCING 90% AT 20X IN BLOOD/BUCCAL FOR NCI (DE VIVO) |
| Aug 1, 2023 | P00001 | $0 | HIGH THROUGHPUT GENOTYPING AND DNA SEQUENCING FOR STUDYING THE GENETIC CONTRIBUTIONS TO HUMAN HEALTH AND DISEASE: WHOLE EXOME SEQUENCING 90% AT 20X IN BLOOD/BUCCAL FOR NCI (DE VIVO) |
| Aug 3, 2021 | 0 | $900.6K | HIGH THROUGHPUT GENOTYPING AND DNA SEQUENCING FOR STUDYING THE GENETIC CONTRIBUTIONS TO HUMAN HEALTH AND DISEASE: WHOLE EXOME SEQUENCING 90% AT 20X IN BLOOD/BUCCAL FOR NCI (DE VIVO) |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.